Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 23:14:1165770.
doi: 10.3389/fphar.2023.1165770. eCollection 2023.

Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data

Kevin McNally  1 , Craig Sams  1 , George Loizou  1
Affiliations

Development, testing, parameterisation, and calibration of a human PBK model for the plasticiser, di (2-ethylhexyl) adipate (DEHA) using in silico, in vitro and human biomonitoring data

Kevin McNally et al. Front Pharmacol. .

Abstract

Introduction: A physiologically based biokinetic model for di (2-ethylhexyl) adipate (DEHA) based on a refined model for di-(2-propylheptyl) phthalate (DPHP) was developed to interpret the metabolism and biokinetics of DEHA following a single oral dosage of 50 mg to two male and two female volunteers. Methods: The model was parameterized using in vitro and in silico methods such as, measured intrinsic hepatic clearance scaled from in vitro to in vivo and algorithmically predicted parameters such as plasma unbound fraction and tissue:blood partition coefficients (PCs). Calibration of the DEHA model was achieved using concentrations of specific downstream metabolites of DEHA excreted in urine. The total fractions of ingested DEHA eliminated as specific metabolites were estimated and were sufficient for interpreting the human biomonitoring data. Results: The specific metabolites of DEHA, mono-2-ethyl-5-hydroxyhexyl adipate (5OH-MEHA), mono-2-ethyl-5-oxohexyl adipate (5oxo-MEHA), mono-5-carboxy-2-ethylpentyl adipate (5cx-MEPA) only accounted for ∼0.45% of the ingested DEHA. Importantly, the measurements of adipic acid, a non-specific metabolite of DEHA, proved to be important in model calibration. Discussion: The very prominent trends in the urinary excretion of the metabolites, 5cx-MEPA and 5OH-MEHA allowed the important absorption mechanisms of DEHA to be modelled. The model should be useful for the study of exposure to DEHA of the general human population.

Keywords: DEHA; PBPK; in silico; plasticiser; reverse dosimetry.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Metabolic pathway of DEHA to the specific, side-chain-oxidized monoesters measured in the controlled human exposure study of (Nehring et al., 2020) and simulated using the PBPK model. The intrinsic clearance, Clint for the biotransformation of MEHA to the two urinary metabolites is shown by the red arrow. Cleavage to the non-specific metabolite adipic acid (AA), and phase II metabolism (conjugation with, e.g., glucuronic acid) not shown for simplification.
FIGURE 2
FIGURE 2
A schema of the model for DEHTP and sub-model for MEHTP. The main model contained a lymphatic compartment (- - - -) which received a portion of oral dose from the stomach and GI tract. Urinary excretion of metabolites was described with a first-order elimination rate constant ascribed to the sub-model.
FIGURE 3
FIGURE 3
Uncertainty analysis of the concentration response profiles in venous blood (mg/l) for DEHA (A) and MEHA (B), and the urinary excretion (mg/h) of 5OH-MEHA (C) and 5cx-MEPA (D).
FIGURE 4
FIGURE 4
Simulation of the urinary excretion (mg/h) of 5OH-MEHA (A) and 5cx-MEPA (B) for volunteer A.
FIGURE 5
FIGURE 5
Simulation of the urinary excretion (mg/h) of 5OH-MEHA (A) and 5cx-MEPA (B) for volunteer B.
FIGURE 6
FIGURE 6
Simulation of the urinary excretion (mg/h) of 5OH-MEHA (A) and 5cx-MEPA (B) for volunteer C.
FIGURE 7
FIGURE 7
Simulation of the urinary excretion (mg/h) of 5OH-MEHA (A) and 5cx-MEPA (B) for volunteer D.
See this image and copyright information in PMC

References

    1. Andersen M. E. (1995). Development of physiologically based pharmacokinetic and physiologically based pharmacodynamic models for applications in toxicology and risk assessment. Toxicol. Lett. 79, 35–44. 10.1016/0378-4274(95)03355-o - DOI - PubMed
    1. Andersen M. E. (2003). Toxicokinetic modeling and its applications in chemical risk assessment. Toxicol. Lett. 138 (1-2), 9–27. 10.1016/s0378-4274(02)00375-2 - DOI - PubMed
    1. Barnabé S., Beauchesne I., Cooper D., Nicell J. (2008). Plasticizers and their degradation products in the process streams of a large urban physicochemical sewage treatment plant. Water Res. 42 (1-2), 153–162. 10.1016/j.watres.2007.07.043 - DOI - PubMed
    1. Barter Z. E., Bayliss M. K., Beaune P. H., Boobis A. R., Carlile D. J., Edwards R. J., et al. (2007). Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: Reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 8 (1), 33–45. 10.2174/138920007779315053 - DOI - PubMed
    1. Barton H. A., Bessems J., Bouvier d'Yvoire M., Buist H., Clewell H., III, Gundert-Remy U., et al. (2009). Principles of characterizing and applying physiologically-based pharmacokinetic and toxicokinetic models in risk assessment. Geneva: World Health Organization.

LinkOut - more resources